Jane A. McKeating

Last updated

Professor Jane A. McKeating
NationalityBritish
Alma mater University of Warwick
University College London
Known forDeputy Head of School of Immunity and Infection (University of Birmingham)
Scientific career
Fields Molecular virology, Microbiology
Institutions University of Birmingham
Website www.birmingham.ac.uk/staff/profiles/iandi/mckeating-jane.aspx

Jane A. McKeating is a professor of molecular biology at Oxford University, and honorary professor at the University of Birmingham, England, where she worked as a professor of molecular virology until 2017. [1] She is listed as a notable scientist in Thomson Reuters' Highly Cited Researchers 2014, ranking her among the top 1% most cited scientists. [2]

Contents

Education

McKeating obtained a Bachelor of Science degree (BSc, Hons) from the University of Warwick in 1982 and a Doctorate from University College London in 1987. [3]

Career

McKeating was a fellow of the Lister Institute of Preventive Medicine from 1994 to 1999. [4]

In 2005, McKeating became professor of molecular virology and deputy head of the School of Immunity and Infection at the University of Birmingham, where she established the school's HCV group which is involved in various national and international collaborative studies.

In 2017, she was appointed as professor of molecular biology at Oxford University, and continues as an honorary professor of the University of Birmingham. [1] In 2019 she became an official fellow of Parks College. [5]

McKeating is a member of the scientific advisory boards for the University of Essen, Astex Pharmaceuticals, and Arrow Pharmaceuticals. [6]

Research areas

McKeating's research focuses on the molecular biology of hepatitis B (HBV) and hepatitis C (HCV), particularly the role of cell surface receptors in the viral life cycle. [7]

Selected publications

Awards and honours

McKeating has won multiple professional awards and fellowships, including:

Related Research Articles

<span class="mw-page-title-main">Interferon</span> Signaling proteins released by host cells in response to the presence of pathogens

Interferons are a group of signaling proteins made and released by host cells in response to the presence of several viruses. In a typical scenario, a virus-infected cell will release interferons causing nearby cells to heighten their anti-viral defenses.

<span class="mw-page-title-main">Hepatitis C</span> Human viral infection

Hepatitis C is an infectious disease caused by the hepatitis C virus (HCV) that primarily affects the liver; it is a type of viral hepatitis. During the initial infection period, people often have mild or no symptoms. Early symptoms can include fever, dark urine, abdominal pain, and yellow tinged skin. The virus persists in the liver, becoming chronic, in about 70% of those initially infected. Early on, chronic infection typically has no symptoms. Over many years however, it often leads to liver disease and occasionally cirrhosis. In some cases, those with cirrhosis will develop serious complications such as liver failure, liver cancer, or dilated blood vessels in the esophagus and stomach.

Hepatitis D is a type of viral hepatitis caused by the hepatitis delta virus (HDV). HDV is one of five known hepatitis viruses: A, B, C, D, and E. HDV is considered to be a satellite because it can propagate only in the presence of the hepatitis B virus (HBV). Transmission of HDV can occur either via simultaneous infection with HBV (coinfection) or superimposed on chronic hepatitis B or hepatitis B carrier state (superinfection).

<span class="mw-page-title-main">Viral hepatitis</span> Liver inflammation from a viral infection

Viral hepatitis is liver inflammation due to a viral infection. It may present in acute form as a recent infection with relatively rapid onset, or in chronic form.

<span class="mw-page-title-main">Hepatitis C virus</span> Species of virus

The hepatitis C virus (HCV) is a small, enveloped, positive-sense single-stranded RNA virus of the family Flaviviridae. The hepatitis C virus is the cause of hepatitis C and some cancers such as liver cancer and lymphomas in humans.

Human Immunodeficiency Virus (HIV) and Hepatitis C Virus (HCV) co-infection is a multi-faceted, chronic condition that significantly impacts public health. According to the World Health Organization (WHO), 2 to 15% of those infected with HIV are also affected by HCV, increasing their risk of morbidity and mortality due to accelerated liver disease. The burden of co-infection is especially high in certain high-risk groups, such as intravenous drug users and men who have sex with men. These individuals who are HIV-positive are commonly co-infected with HCV due to shared routes of transmission including, but not limited to, exposure to HIV-positive blood, sexual intercourse, and passage of the Hepatitis C virus from mother to infant during childbirth.

<span class="mw-page-title-main">CXCL10</span> Mammalian protein found in Homo sapiens

C-X-C motif chemokine ligand 10 (CXCL10) also known as Interferon gamma-induced protein 10 (IP-10) or small-inducible cytokine B10 is an 8.7 kDa protein that in humans is encoded by the CXCL10 gene. C-X-C motif chemokine 10 is a small cytokine belonging to the CXC chemokine family.

<span class="mw-page-title-main">Vincent Racaniello</span> American biologist

Vincent R. Racaniello is a Higgins Professor in the Department of Microbiology and Immunology at Columbia University's College of Physicians and Surgeons. He is a co-author of a textbook on virology, Principles of Virology.

<span class="mw-page-title-main">E2 (HCV)</span>

E2 is a viral structural protein found in the hepatitis C virus. It is present on the viral envelope and functions as a host receptor binding protein, mediating entry into host cells. It is a key target for the design of entry inhibitors and vaccine immunogens.

<span class="mw-page-title-main">NS5A (hepacivirus)</span>

Nonstructural protein 5A (NS5A) is a zinc-binding and proline-rich hydrophilic phosphoprotein that plays a key role in Hepatitis C virus RNA replication. It appears to be a dimeric form without trans-membrane helices.

<i>Hepatitis B virus</i> Species of the genus Orthohepadnavirus

Hepatitis B virus (HBV) is a partially double-stranded DNA virus, a species of the genus Orthohepadnavirus and a member of the Hepadnaviridae family of viruses. This virus causes the disease hepatitis B.

miR-122

miR-122 is a miRNA that is conserved among vertebrate species. miR-122 is not present in invertebrates, and no close paralogs of miR-122 have been detected. miR-122 is highly expressed in the liver, where it has been implicated as a regulator of fatty-acid metabolism in mouse studies. Reduced miR-122 levels are associated with hepatocellular carcinoma. miR-122 also plays an important positive role in the regulation of hepatitis C virus replication.

<span class="mw-page-title-main">Michael Houghton (virologist)</span> British virologist

Sir Michael Houghton is a British scientist and Nobel Prize laureate. Along with Qui-Lim Choo, George Kuo and Daniel W. Bradley, he co-discovered Hepatitis C in 1989. He also co-discovered the Hepatitis D genome in 1986. The discovery of the Hepatitis C virus (HCV) led to the rapid development of diagnostic reagents to detect HCV in blood supplies, which has reduced the risk of acquiring HCV through blood transfusion from one in three to about one in two million. It is estimated that antibody testing has prevented at least 40,000 new infections per year in the US alone and many more worldwide.

<span class="mw-page-title-main">Gamal Esmat</span>

Gamal Esmat is a professor at Endemic Medicine and Hepatogastroenterology Department, Cairo University. He was vice president of Cairo University for Graduate Studies and Research.

<span class="mw-page-title-main">Discovery and development of NS5A inhibitors</span>

Nonstructural protein 5A (NS5A) inhibitors are direct acting antiviral agents (DAAs) that target viral proteins, and their development was a culmination of increased understanding of the viral life cycle combined with advances in drug discovery technology. However, their mechanism of action is complex and not fully understood. NS5A inhibitors were the focus of much attention when they emerged as a part of the first curative treatment for hepatitis C virus (HCV) infections in 2014. Favorable characteristics have been introduced through varied structural changes, and structural similarities between NS5A inhibitors that are clinically approved are readily apparent. Despite the recent introduction of numerous new antiviral drugs, resistance is still a concern and these inhibitors are therefore always used in combination with other drugs.

<span class="mw-page-title-main">Narlaprevir</span> Chemical compound

Narlaprevir, is an inhibitor of NS3/4A serine protease, intended for the treatment of chronic hepatitis C caused by genotype 1 virus in combination with other antiviral drugs.

Hepatitis C virus (HCV) genotypes refer to the genetic variations that occurs in the hepatitis C virus. Hepatitis C is a contagious disease that primarily affects the liver, causing severe damage as the disease progresses. It is caused by the Hepatitis C virus, a small, enveloped RNA virus. The transmission of hepatitis C is through the contact with the blood of the infected person, for example by sharing the needles or by using non-sterile medical equipment. HCV is transmitted globally because of the high infection rate and is also associated with a high mortality rate. The World Health Organization indicates the 3.3% of the world population is infected by the HCV virus. Statistical records show that there are about 13 million HCV affected persons in Сhina, 3.5 million affected persons in the United States, and about 10 million people are affected by HCV in Pakistan. In all cases, the viral genotype of the HCV stays the same, occasionally mutations do occur making the treatment more complex by targeting the changes in the genotype. Hepatitis C virus genotype is considered more common than the Hepatitis B virus infection contributing to more than a million cases annually and is considered one of the major reason for liver transplantation in United States. Some of the HCV genotypes may develop in people without symptoms leading to dangerous conditions like liver cirrhosis causing a permanent damage to liver and the unnoticed HCV conditions will affect brain, joints, blood vessels, bones, and kidneys.

Christian Bréchot is a French physician and scientist who has been serving as president of the Global Virus Network (GVN) since 2017. He previously served as president of the Institut Pasteur from 2013 until 2017 and as chief executive officer of the French National Institute for Health and Medical Research (INSERM) from 2001 to 2007.

Saumitra Das is an Indian microbiologist and a professor at the Department of Microbiology and Cell Biology of the Indian Institute of Science. Known for his studies in the fields of molecular virology and molecular biology, Das is an elected fellow of all the three major Indian science academies namely, the Indian Academy of Sciences, the National Academy of Sciences, India and the Indian National Science Academy. The Department of Biotechnology of the Government of India awarded him the National Bioscience Award for Career Development, one of the highest Indian science awards, for his contributions to biosciences in 2005.

Francis "Frank" Vincent Chisari is a physician, experimental pathologist, virologist, and immunologist, known for his research on virus-host interactions of hepatitis B and hepatitis C.

References

  1. 1 2 "University of Oxford Medical Sciences Division" . Retrieved 18 February 2018.
  2. "Highly Cited Researchers 2014". highlycited.com. Retrieved 16 April 2015.
  3. "Jane A. McKeating". Technical University of Munich . Retrieved 31 May 2023.
  4. "Former Fellows". lister-institute.org.uk. Retrieved 17 April 2015.
  5. "Parks College People". University of Oxford. Retrieved 29 November 2019.
  6. "University of Birmingham, Viral Hepatitis Research – Jane McKeating" . Retrieved 6 April 2015.
  7. "Stop-HCV, Stratified Medicine for HepC – Jane McKeating" . Retrieved 6 April 2015.